Survival benefit in advanced or metastatic breast cancer with visceral metastases

Article

Findings from a new study show significant overall survival benefit of Novartis’ ribociclib in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer with visceral metastases.

The findings are from a subgroup analysis of the phase 3 MONALESSA-3 and MONALEESA-7 trials and were presented during the ASCO20 Virtual Scientific Program.

Learn more and read the full article from Drug Topics.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
USPSTF releases new recommendations for breast cancer screening | Image Credit: uclahealth.org
Related Content
© 2025 MJH Life Sciences

All rights reserved.